During the past decade, Sarah Cannon Research Institute conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Research Institute" #1 sponsor was "Odonate Therapeutics, Inc." with 3 trials, followed by "Erasca, Inc." with 2 trials sponsored, "American Society of Clinical Oncology" with 1 trials sponsored, "Baxalta now part of Shire" with 1 trials sponsored and "Clovis Oncology, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute" are "Breast Cancer" (3 trials), "Advanced or Metastatic Solid Tumors" (2 trials), "Colorectal Cancer" (2 trials), "Advanced Solid Tumor With Evidence of Germline or Somatic BRCA" (1 trials) and "Advanced Solid Tumors or Lymphomas" (1 trials). Many other conditions were trialed in "Sarah Cannon Research Institute" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Research Institute" are "Drug" (11 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "ERAS-601" (2 trials), "Pembrolizumab" (2 trials), "Tesetaxel" (2 trials) and "Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Research Institute" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Sarah Cannon Research Institute". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Sarah Cannon Research Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Research Institute, 9 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".